To the Editor We read with interest the study published by Cohen et al.1 This was a randomized clinical trial comparing the benefits of Roux-en-Y gastric bypass (RYGB) with best medical treatment (BMT) for chronic kidney disease in patients with type 2 diabetes and grade 1 obesity (body mass index of 30-35; calculated as weight in kilograms divided by height in meters squared).1 The authors concluded that RYGB is more effective at achieving microalbuminuria remission after 24 months and demonstrated it is a safe procedure with similar adverse effects to medical management.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ganesananthan S, Woo T, Li C. The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes. JAMA Surg. 2021;156(2):204–205. doi:10.1001/jamasurg.2020.5177
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.